Week In Review: I-Mab Seeking $2 Billion Deal For CD-47 Candidate

I-Mab BioPharma of Shanghai is shipping its CD-47 immunoncology candidate to various global biopharmas with hopes of forming a $2 billion collaboration. I-Mab believes TJC4 is a potential global CD47 because it binds to a unique epitope on CD47.